{"nctId":"NCT01180647","briefTitle":"Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail","startDateStruct":{"date":"2010-05"},"conditions":["Opiate Dependence"],"count":48,"armGroups":[{"label":"Extended-release naltrexone (XR-NTX)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Extended-Release Naltrexone"]},{"label":"Motivational Enhancement Counseling Only","type":"PLACEBO_COMPARATOR","interventionNames":["Behavioral: Motivational Enhancement Counseling"]}],"interventions":[{"name":"Extended-Release Naltrexone","otherNames":["Vivitrol"]},{"name":"Motivational Enhancement Counseling","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults incarcerated in NYC jails with known release date\n* DSM-IV criteria for current opioid dependence\n* No current agonist (methadone, buprenorphine) treatment\n* Currently opioid free by history ('detoxed') and with a negative urine for all opioids\n* General good health as determined by complete medical interview and physical examination\n* Age 18-60 years.\n\nExclusion Criteria:\n\n* History of liver failure, cirrhosis, or recent liver function test levels greater than three times normal\n* Pregnancy, lactation, or planning conception\n* Active medical illness that might make participation hazardous\n* Untreated psychiatric disorder\n* History of allergic reaction to naltrexone, PLG (polylactide co-glycolide), carboxymethylcellulose, or any other components of the diluent.\n* Current chronic pain condition treated with opioids.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Post-Release Opioid Relapse","description":"Post-release opioid relapse at week 4, measured by self-report (Time Line Follow Back) and urine toxicologies, and defined as ≥10 of 28 days of self-reported opioid misuse following jail release or two or three positive of the three urine samples during weeks 2, 3 and 4. A single positive or missing urine result counted as 7 opioid misuse days.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Participation in Community Drug Treatment Post-release","description":"This secondary outcome tracks community drug treatment initiation four weeks post-release from jail. Measured by self-report community drug treatment initiation at week 4 study visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Any Opioid Use Post-release","description":"Counts of any opioid use, defined as self-reported ≥ 1 day of heroin or other opioid use as measured by the Timeline Follow-Back assessment during the first 4 weeks post-release.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Injection Drug Use Post-release","description":"This secondary outcome tracks any injection drug use and frequency of injection drug use in the four weeks following release from jail.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Accidental Drug Overdose","description":"Accidental drug overdose is defined as patient self-report of any event consistent with over-sedation or respiratory suppression following ingestion of alcohol, prescription, or illicit drugs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events and Serious Adverse Events","description":"AEs and SAEs per standard definitions will be measured by self-report.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Anticipated XR-NTX Symptoms","Shoulder Seperation","Respiratory Problems"]}}}